EBSNYSEPharmaceutical PreparationsFiscal year ends December 31
Emergent BioSolutions Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$6.36−0.02 (-0.31%)
Close on Oct 19, 2026
- Market cap
- $328.18M
- P/E (TTM)
- –
- Dividend yield
- –
Emergent BioSolutions statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Emergent BioSolutions | Industry median |
|---|---|---|
| Market Cap | $326.10M | $166.30M |
| Enterprise Value | $768.20M | $88.19M |
| PS Ratio | 0.42 | 3.65 |
| PB Ratio | 0.96 | 2.03 |
| P/TBV Ratio | 4.10 | 2.29 |
| P/FCF Ratio | 3.80 | 17.44 |
| P/OCF Ratio | 3.34 | 12.98 |
Enterprise value
| Measure | Emergent BioSolutions | Industry median |
|---|---|---|
| EV / Sales | 1.00 | 2.51 |
| EV / EBITDA | 27.05 | 14.65 |
| EV / FCF | 8.94 | 20.86 |
Income (trailing twelve months)
| Measure | Emergent BioSolutions | Industry median |
|---|---|---|
| Revenue | $770.20M | $58.34M |
| Gross Profit | $430.30M | $105.94M |
| Operating Income | -$66.00M | -$21.40M |
| Pretax Income | -$146.00M | -$14.34M |
| Net Income | -$176.80M | -$22.46M |
| EBITDA | $28.40M | -$16.91M |
| EPS (Diluted) | -$3.47 | -$0.83 |
Margins
| Measure | Emergent BioSolutions | Industry median |
|---|---|---|
| Gross Margin | 55.9% | 52.9% |
| Operating Margin | -8.57% | -44.0% |
| Pretax Margin | -19.0% | -13.3% |
| Profit Margin | -23.0% | -40.2% |
| EBITDA Margin | 3.69% | -30.2% |
| FCF Margin | 11.2% | -9.27% |
Returns
| Measure | Emergent BioSolutions | Industry median |
|---|---|---|
| Return on Equity (ROE) | -40.3% | -53.2% |
| Return on Assets (ROA) | -14.0% | -40.9% |
| Return on Invested Capital (ROIC) | -6.06% | -32.4% |
| Return on Capital Employed (ROCE) | -6.64% | -38.1% |
Growth
| Measure | Emergent BioSolutions | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -9.56% | 5.96% |
| Net Income Growth (YoY) | -226.7% | -35.2% |
| EPS Growth (YoY) | -241.6% | -26.2% |
| FCF Growth (YoY) | -44.6% | 2.34% |
| Revenue Growth (3Y CAGR) | -12.7% | 2.25% |
| Revenue Growth (5Y CAGR) | -14.0% | 6.48% |
| EPS Growth (5Y CAGR) | -30.4% | 3.77% |
Balance sheet
| Measure | Emergent BioSolutions | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $139.70M | $61.43M |
| Total Debt | $581.80M | $118.52M |
| Net Cash (Debt) | -$442.10M | $15.35M |
| Net Cash Per Share | -$8.62 | $0.66 |
| Equity (Book Value) | $341.40M | $49.09M |
| Book Value Per Share | $6.66 | $1.37 |
| Tangible Book Value | $79.60M | $23.52M |
| Working Capital | $543.20M | $76.81M |
Financial position
| Measure | Emergent BioSolutions | Industry median |
|---|---|---|
| Current Ratio | 5.42 | 3.34 |
| Quick Ratio | 2.68 | 2.44 |
| Debt / Equity | 1.70 | 0.52 |
| Debt / EBITDA | 20.49 | 3.44 |
| Debt / FCF | 6.77 | 4.89 |
| Net Debt / EBITDA | 15.57 | 2.36 |
| Interest Coverage | -1.30 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Emergent BioSolutions | Industry median |
|---|---|---|
| Operating Cash Flow | $97.70M | -$12.35M |
| Capital Expenditures | -$11.80M | -$1.08M |
| Free Cash Flow | $85.90M | -$20.22M |
| FCF Per Share | $1.68 | -$0.42 |
Efficiency
| Measure | Emergent BioSolutions | Industry median |
|---|---|---|
| Asset Turnover | 0.61 | 0.39 |
| Inventory Turnover | 1.06 | 2.70 |
| Revenue Per Employee | $855.78K | $404.87K |
| Profits Per Employee | -$196.44K | -$703.34K |
| Employee Count | 900 | 74 |
Dividends and yields
| Measure | Emergent BioSolutions | Industry median |
|---|---|---|
| Earnings Yield | -54.2% | -23.3% |
| FCF Yield | 26.3% | -8.72% |
| Buyback Yield | 11.0% | -0.59% |
| Shareholder Yield | 11.0% | 0.00% |
Shares
| Measure | Emergent BioSolutions | Industry median |
|---|---|---|
| Shares Outstanding | 51,273,300 | 58,127,000 |
| Shares Change (YoY) | 0.00% | 10.9% |
| Shares Change (QoQ) | -0.97% | 0.54% |
| Float | 48,192,100 | 49,136,700 |
| Shares Held by Insiders | 6.01% | 11.6% |
| Shares Held by Institutions | 87.1% | 59.4% |
Taxes
| Measure | Emergent BioSolutions | Industry median |
|---|---|---|
| Income Tax | $30.80M | $79.87K |
Scores
| Measure | Emergent BioSolutions | Industry median |
|---|---|---|
| Altman Z-Score | 0.91 | -0.22 |
| Piotroski F-Score | 7 | 4 |
| Beneish M-Score | -3.56 | -2.62 |
Calculated by StockData from Emergent BioSolutions's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.